# Syntaxin

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syntaxin

- Industry: Biotechnology
- Headquarters: UK
- Website: www.syntaxin.com
- Total disclosed funding: $66M
- Latest round: Series C (Nov 11, 2010)
- Investors on record: 9

## About

Syntaxin is a UK-based company specializing in premium domain name services, offering domain acquisition, management, and transfer solutions to enhance digital identity for businesses and individuals.Founded in 2005 in the UK, Syntaxin focuses on providing premium domain name services. In July 2013, the company was acquired by Ipsen for EUR 28 million. The company has completed five deals to date. The founder's details are not publicly available.Syntaxin provides a range of digital products and services centered on premium domain name acquisition, management, and transfer. The services cater to startups, established brands, and investors looking to strengthen their online presence with valuable digital assets. The company targets various industries globally, including North America, Europe, and parts of Asia, addressing challenges related to online visibility and brand recognition.In 2023, Syntaxin reported a revenue of EUR 468,963.50. The company's revenue is primarily generated through the sale and transfer of premium domain names and related management services, which are priced based on market demand and perceived value.Following the acquisition in July 2013, the funding of EUR 28 million will be allocated to support the development and commercial progress of new products. Syntaxin plans to enhance its service offerings and expand into new markets, focusing on strategic growth by targeting emerging regions within Europe and Asia by 2025.

## Funding rounds

- Series C, Nov 11, 2010, $29M — Abingworth, Seventure Partners, EQT Life Sciences, SR One, Johnson & Johnson Innovation, Quest Capital, Ipsen, Lundbeckfond Ventures
- Series B, Oct 1, 2007, $32M — Abingworth, EQT Life Sciences, SR One, Johnson & Johnson Innovation, Quest Management
- Series A, Nov 14, 2005, $5.3M — Abingworth

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B, Series C
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B, Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B, Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B, Series C
- Quest Management (https://capitalatlas.ai/funds/quest-management) — Series B
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series C
- Quest Capital (https://capitalatlas.ai/funds/quest-capital) — Series C
- Ipsen — Series C
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series C